Lu, KaiKaiLuWang, Hsin-ChiaoHsin-ChiaoWangTu, Yi-ChenYi-ChenTuChang, Cheng-ChungCheng-ChungChangPEI-JEN LOUChang, Ta-ChauTa-ChauChangJING-JER LIN2024-02-192024-02-192023-11-0800278874https://scholars.lib.ntu.edu.tw/handle/123456789/639783Osimertinib is the first-line therapy for patients with non-small cell lung cancer harboring epidermal growth factor receptor-activating alterations. Although osimertinib has been shown to elicit profound patient responses, cancer cells frequently develop additional alterations that sustain their proliferation capacity. This acquired resistance represents a substantial hurdle in precision medicine for patients with lung cancer.enjournal article10.1093/jnci/djad142374817102-s2.0-85180580878https://api.elsevier.com/content/abstract/scopus_id/85180580878